We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Pascal’s wager

8 June 2020 By Neil Unmack, Aimee Donnellan

The $140 bln drugmaker approached U.S. rival Gilead about a merger, Bloomberg reported. The combination lacks strategic logic and looks unlikely. CEO Pascal Soriot has done well for investors. The risk is AstraZeneca’s debt load, or his bigger ambitions, threaten that record.

This content is for Subscribers only

or
If you need assistance please email breakingviews.clientsupport@thomsonreuters.com
 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)

We need you to verify your email address to continue. Please check your email/junk folder for our verification request.

Click here to resend the verification email.